Patients with severe hypertriglyceridaemia (sHTG) are often refractory to lipid-lowering therapy. Apolipoprotein (Apo) CIII inhibition could be promising to treat subjects with sHTG. The antisense oligonucleotide against APOC3 mRNA volanesorsen was recently introduced to treat sHTG. We performed a systematic review and meta-analysis of RCTs on the efficacy and safety of volanesorsen as compared to placebo treatment in patients with severe HTG.
Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials / Calcaterra, Ilenia; Lupoli, Roberta; Di Minno, Alessandro; Di Minno, Matteo Nicola Dario. - In: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. - ISSN 1365-2362. - 52:11(2022). [10.1111/eci.13841]
Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials
Calcaterra, Ilenia;Lupoli, Roberta;Di Minno, Alessandro;Di Minno, Matteo Nicola Dario
2022
Abstract
Patients with severe hypertriglyceridaemia (sHTG) are often refractory to lipid-lowering therapy. Apolipoprotein (Apo) CIII inhibition could be promising to treat subjects with sHTG. The antisense oligonucleotide against APOC3 mRNA volanesorsen was recently introduced to treat sHTG. We performed a systematic review and meta-analysis of RCTs on the efficacy and safety of volanesorsen as compared to placebo treatment in patients with severe HTG.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
